

S4 Table. Patients characteristics and results of serial sequencing before and after RT

No.	Age (yr)	Sex	Histology	Size (cm)	Stage	RT Dose (Gy)	Dose/ fraction (Gy)	ctDNA (Maximum VAF, %)		
								Pre-RT	During-RT	1 month after RT
1	78	M	SCC	4.8	T2bN1	66	3	0.12	0.85	0.26
2	75	M	SCC	3.3	T2aN0	60	4	0.13	0.52	0.30
3	82	M	N/P	1.9	T1bN0	64	8	0.04	0.52	0.07
4	78	F	ADC	3.7	T2aN0	64	4	0.67	1.25	0.20
5	70	M	SCC	1.6	T1bN1	60	15	2.32	1.38	0.88
6	62	F	SCC	4.6	T4N0	60	4	2.79	4.14	0.05
7	74	M	SCC	5.2	T3N0	60	4	1.29	0.98	1.82
8	75	M	SCC	3.1	T3N0	64	8	2.43	2.58	0
9	71	M	SCC	3.1	T2aN0	64	8	2.87	0.06	0
10	57	M	N/P	4.4	T2bN0	60	15	4.82	7.79	0.09
11	70	M	ADC	3.3	T2aN0	60	7.5	0.83	1.21	0.79

ADC, adenocarcinoma; N/P, not proven; RT, radiotherapy; SCC, squamous cell carcinoma; VAF, variant allele frequency.